CM
PRAX icon

Castleark Management’s Praxis Precision Medicines PRAX Stock Holding History

Castleark Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.17M Buy
+24,390
New +$7.72M 0.22% 114

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Castleark Management's PRAX Position: Q2 2026 in Review

Castleark Management opened a new position in Praxis Precision Medicines (PRAX) in Q2 2026: 24,390 shares worth $8.17M. The stake represents 0.22% of the portfolio and ranks #114 among its holdings.

309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Castleark Management held 24,390 shares of Praxis Precision Medicines worth $8.17M as of Q2 2026.
  • Praxis Precision Medicines was a new Castleark Management position in Q2 2026.
  • Praxis Precision Medicines made up 0.22% of Castleark Management's portfolio in Q2 2026, its #114 holding.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.